Company Profile
Salarius Pharmaceuticals Stock Price, News & Analysis
Company overview
Business overview
Salarius Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Salarius Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Salarius Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Salarius Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
SLRX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Salarius is a legacy / closeout story now, so the catalysts are any remaining strategic or asset-resolution update rather than a live oncology milestone. The market is mainly focused on residual value.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Source: Salarius Pharmaceuticals
- 04
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
Source: Salarius Pharmaceuticals
- 05
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Source: Salarius Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.